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SUMMARY  
Objective: Glucocorticoids have been shown to improve outcome in community-acquired 
pneumonia (CAP). However, glucocorticoids have potential side-effects, and treatment 
response may vary. It is thus crucial to select patients with high likelihood to respond 
favorably. In critical illness, cosyntropin testing is recommended to identify patients in need 
for glucocorticoids. We investigated whether consyntropin testing predicts treatment 
response to glucocorticoids in CAP.  
Design: Predefined secondary analysis of a randomized controlled trial 
Patients: Hospitalized patients with CAP 
Measurements: We performed 1µg cosyntropin tests in a randomized trial comparing 
prednisone 50mg for seven days to placebo. We investigated whether subgroups based on 
baseline and stimulated cortisol levels responded differently to glucocorticoids with regards 
to time to clinical stability (TTCS) and other outcomes by inclusion of interaction terms into 
statistical models. 
Results: 326 patients in the prednisone and 309 patients in the placebo group were 
evaluated. Neither basal cortisol nor a Δcortisol<250nmol/L after stimulation nor the 
combination of basal cortisol and Δcortisol predicted treatment response as measured by 
TTCS (all p for interaction>0.05). Similarly, we found no effect modification with respect to 
mortality, rehospitalization, antibiotic treatment duration or CAP-related complications (all p 
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for interaction>0.05). However, glucocorticoids had a stronger effect on shortening length of 
hospital stay in patients with a baseline cortisol of ≥938 nmol/L (p for interaction=0.015). 
Conclusions: Neither baseline nor stimulated cortisol after low-dose cosyntropin testing at a 
dose of 1 µg predicted glucocorticoid responsiveness in mild to moderate CAP. A treatment 
decision for or against adjunct glucocorticoids in CAP should not be made depending on 
cortisol values or cosyntropin testing results. 
 
Keywords: glucocorticoids, ACTH test, cosyntropin test, adrenal function, Community-
acquired Pneumonia, Critical-Illness-related Corticosteroid Insufficiency 
 
ABBREVIATIONS 
ACTH: adrenocorticotropic hormone 
ARDS: acute respiratory distress syndrome 
CAP: community-acquired pneumonia 
CI: confidence interval 
CIRCI: Critical illness – related corticosteroid insufficiency 
CRP: C-reactive protein 
HPA axis: hypothalamo-pituitary-adrenal axis 
HR: Hazard ratio 
ICU: intensive care unit 
IQR: interquartile range 
LOS: length of stay 
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PSI: pneumonia severity index 
SD: standard deviation 
TTCS: time to clinical stability 
 
INTRODUCTION 
There is increasing evidence that glucocorticoids improve outcome in community-acquired 
pneumonia (CAP) through their anti-inflammatory effects, thus attenuating the systemic 
inflammatory process. Two recent meta-analyses have shown that glucocorticoids 
significantly reduce time to clinical stability (TTCS), length of hospital stay (LOS), rates of 
intensive care unit (ICU) admittance and acute respiratory distress syndrome (ARDS) 
without an increase in complications. No significant effect on mortality was found, albeit a 
trend towards lower mortality.1,2 Importantly, CAP patients are an inhomogeneous 
population, and it is unreasonable to assume that all of these patients would respond equally 
well to the same immunomodulatory agent 3. Therefore, it is crucial to select those patients 
with a positive treatment response to glucocorticoids.  
Severe illness activates the hypothalamo-pituitary-adrenal (HPA) axis with increased levels 
of cortisol.4 In critically ill patients, there is evidence that the HPA axis is impaired in some of 
them, and it has been put forward that cortisol may not increase enough to cover the need to 
survive.5-7 This concept was recently named critical illness-related corticosteroid insufficiency 
(CIRCI)8. With this rationale, it is recommended in critical illness to select patients in need for 
glucocorticoid treatment by cosyntropin testing.8-10 For CAP outside of critical illness, no data 
are available investigating the predictive value of cosyntropin testing to identify patients with 
pronounced systemic inflammatory response who will respond to glucocorticoid treatment. 
We, therefore, aimed to evaluate whether cosyntropin testing identifies those patients who 
profit most from adjunct glucocorticoid treatment in CAP.  
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MATERIALS AND METHODS 
Study design and participants 
This is a preplanned secondary analysis of a randomized, double-blind, placebo-controlled 
multicenter trial comparing prednisone to placebo in patients hospitalized with CAP of any 
severity. Patients were recruited within 24 hours of admission in emergency departments of 
seven tertiary care hospitals in Switzerland from December 1, 2009, to May 21, 2014. The 
study details have been published elsewhere.11 In brief, consecutive patients hospitalized 
with CAP were randomized upon admission to 50 mg prednisone for seven days or placebo.  
The results of the main study showed a benefit of glucocorticoids in CAP.12  
Inclusion criteria were age above 18 years and hospital admission with CAP. CAP was 
defined by a new infiltrate on chest radiograph and the presence of at least one of the 
following acute respiratory signs and one of the following symptoms: cough, sputum 
production, dyspnea, temperature of 38.0°C or higher, findings of abnormal breathing 
sounds or rales on auscultation, leucocyte count higher than 10 x 109/L or less than 4 x 
109/L. Exclusion criteria were permanent inability for informed consent, active intravenous 
drug use, acute burn injury, gastrointestinal bleeding within the past three months, known 
adrenal insufficiency, a condition requiring more than 0.5mg/kg per day prednisone 
equivalent, pregnancy or breastfeeding, and severe immunosuppression defined as one of 
the following: infection with human immunodeficiency virus and a CD4 cell count below 0.35 
x 109/L, immunosuppressive therapy after solid organ transplantation, neutropenia below 0.5 
x 109/L , or neutrophils of 0.5 x -1 x 109/L during ongoing chemotherapy with an expected 
decrease to values below 0.5 x 109/L , cystic fibrosis, or active tuberculosis.  
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Ethics statement 
The conduct of the trial adhered to the declaration of Helsinki and Good Clinical Practice 
Guidelines, and ethical committees of all participating hospitals (ethics committees: 
Ethikkommission beider Basel EKBB (Reference Number 370/08), Ethikkommission der 
Kantone Aargau und Solothurn (Reference Number 2011/031), commission d’ethique 
Lausanne (Reference Number 116/10) and Ethikkommission Bern (Reference Number 
193/11)) as well as the Swiss Agency for Therapeutic Products (SWISSMEDIC (Reference 
Number 2009DR3227)) approved the study protocol before patient recruitment. All 
participants signed and received a copy of a written informed consent form before taking part 
in the study. The trial was registered with ClinicalTrials.gov, number NCT00973154, on 7 
September 2009. It complies with the CONSORT 2010 statement. 
 
Procedures, assays and laboratory values 
After informed consent was obtained, blood was drawn and basal cortisol was measured. 
Then, a low-dose cosyntropin test was performed by administration of 1 µg cosyntropin. 1 
microgram cosyntropin tests were performed using 0.25 mg tetracosactidum (0.250 mg/mL 
synthetic ACTH1–24, Synacthen©, Novartis Pharma, Switzerland) divided into 0.001mg 
tetracosactidum doses by the pharmacy of the University Hospital Basel (Basel, 
Switzerland), as described elsewhere 13,14. After 25-30 min, blood was again drawn and 
stimulated cortisol was measured. Study medication was started after completion of the low-
dose cosyntropin testing. Timing of cosyntropin testing was performed at time of study 
inclusion or, if study inclusion occurred after 8 p.m., in the next morning. In the case of 
delayed cosyntropin testing, the first dose of study medication was delayed as well. 
Cortisol was measured by the commercially available and routinely used assay during 
weekdays at the corresponding study center (for assay specifications, see Table 2).  
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Study nurses assessed patients for clinical stability every 12 h during hospital stay. All 
patients were treated according to published CAP guidelines.15  
Baseline data included medical history items, relevant comorbidities, clinical items of 
pneumonia, and all variables required for the calculation of the pneumonia severity index 
(PSI)16. Structured follow-up telephone interviews for secondary outcomes after discharge 
were done on day 30. 
 
Endpoints 
The primary endpoint TTCS was defined as time (days) until vital signs were stable for 24 h 
or longer. Stable vital signs were defined as a temperature of 37.8°C or lower, heart rate of 
100 beats per min or lower, spontaneous respiratory rate of 24 breaths per min or lower, 
systolic blood pressure of 90 mm Hg or higher (≥100 mm Hg for patients diagnosed with 
hypertension) without vasopressor support, mental status back to level before occurrence of 
community-acquired pneumonia, ability for oral intake, and adequate oxygenation on room 
air (PaO₂ ≥60 mm Hg or pulse oximetry ≥90%). These stability criteria were based on 
current CAP treatment recommendations. 17 Instability was defined if at least one of these 
criteria were not met. 
Secondary endpoints were length of hospital stay, mortality at 30 days, rehospitalization, 
length of total and intravenous antibiotic treatment, and incidence of complications from 
pneumonia (recurrence, ICU stay, rehospitalization, acute respiratory distress syndrome 
(ARDS), empyema, nosocomial infection, and delirium) 
For both primary and secondary endpoints, we tested constellations of baseline and / or 
stimulated cortisol levels which have been reported 10,18,19 and proposed 8,9 to predict 
treatment response to glucocorticoids. This included the following constellations: 
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- Δcortisol < 250 nmol/L as the suggested cut-off defining an insufficient increase of 
cortisol after cosyntropin testing in critically ill 9,20  
- Baseline cortisol ≥ 938 and/or Δcortisol < 250 nmol/L as proposed by Annane et al. 
9,18  
- Baseline cortisol ≥ 571 nmol/L and/or Δcortisol < 250 nmol/L as the median cortisol 
value of our studied CAP cohort 12  
- Critical illness-related corticosteroid insufficiency (CIRCI) defined as baseline cortisol 
< 414, as proposed by Goodman et al. 19,20  
- CIRCI defined as baseline cortisol < 275.9 and/or Δcortisol < 250 nmol/L according to 
the consensus statement 2008 of the American College of Critical Care Medicine 8,10  
 
Statistical analysis 
For the analysis of adrenal function, we evaluated patients in the per-protocol population, i.e. 
patients fully complying with the trial protocol. For the primary endpoint, we performed Cox 
regression models for TTCS to compare baseline and stimulated cortisol levels between 
both treatment groups. Patients who died before achieving clinical stability were censored at 
the day of death; all surviving patients not achieving clinical stability were censored at day 
30. For the primary endpoint, none of the patients was lost to follow-up. For all secondary 
endpoints, we calculated estimates of the effect size and corresponding 95% confidence 
intervals (CI) using Cox proportional hazards regression. For all time-to-event analyses of 
secondary endpoints, patients lost to follow-up were censored at the time of last contact; for 
all other analyses of secondary outcomes we used complete case analyses. To test for 
effect modification, we included interaction terms into the statistical models and report p 
values. All reported CIs are two-sided 95% intervals, and tests were done at the two-sided 
5% significance level. STATA 12.1 (Stata Corp, College Station, Texas) was used for data 
analysis.  
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RESULTS 
Baseline characteristics 
A total of 326 patients in the prednisone group and 309 patients in the placebo group who 
were treated per protocol had complete cosyntropin test values and were included in this 
analysis (figure 1, study flow chart). 
Baseline characteristics of the two treatment groups are shown in table 1. Median age of 
patients was 73 years, and 396 patients (62 %) were men. Patients had a high burden of 
comorbidities including diabetes, chronic obstructive pulmonary disease, chronic heart 
failure, and chronic renal insufficiency. About half the patients were in high-risk PSI classes 
IV and V. Baseline and stimulated cortisol levels were 573 nmol/L (402-741) and 877 nmol/L 
(715-1038) in the prednisone group and 563 nmol/L (389-751) and 849 nmol/L (707-1065) in 
the placebo group, respectively. Δcortisol upon stimulation was 295 nmol/L (188-401) in the 
prednisone group and 290 nmol/L (301-397) in the placebo group. 
 
Primary endpoint 
Basal plasma cortisol levels did not predict treatment response to prednisone in any of the 
subgroups tested with similar effects with respect to TTCS (Hazard ratios (HR) between 1.15 
and 1.66, p for interaction > 0.05 for all subgroups). Similarly, neither a Δcortisol < 250 
nmol/L after cosyntropin testing nor the three predefined combinations of basal cortisol and 
Δcortisol tested (baseline ≥ 938nmol/L and Δcortisol < 250nmol/L; baseline ≥ 571nmol/L and 
Δcortisol < 250nmol/L; baseline < 275.9 or Δcortisol < 250 nmol/L) predicted treatment 
response to glucocorticoids (p for interaction > 0.05 for all subgroups; figure 2a).  
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Secondary Endpoints 
Basal plasma cortisol levels or Δcortisol after cosyntropin testing (whichever of the tested 
cutoffs used) did not predict treatment response to glucocorticoids with regards to 30-day 
mortality, rehospitalization, length of total or intravenous antibiotic treatment, or incidence of 
CAP complications (p for interaction > 0.05 for all subgroups; figures 2b to 2d and 
supplemental table S1 for detailed values). However, patients with a baseline cortisol value 
of ≥ 938 nmol/L had a significantly shorter length of hospital stay in the prednisone group as 
compared to the placebo group (regression coefficient -4.34 days (95% CI -8.05- -0.63) for 
patients with baseline cortisol ≥ 938 nmol/L, vs. -0.83 days (95% CI -1.76-0.11) for patients 
with baseline cortisol < 938 nmol/L; p for interaction = 0.015; figure 2b and supplemental 
table S2).  
 
DISCUSSION 
The main finding of our study is that - irrespective of which cutoff was used - neither baseline 
nor stimulated cortisol after cosyntropin testing predicted responsiveness to glucocorticoid 
treatment in CAP. There was only a slightly better glucocorticoid treatment effect with 
regards to LOS in patients with a high baseline cortisol ≥ 938 nmol/L, which might be a 
chance finding due to multiple testing. The “high risk” group described by Annane et al, 
characterized by maximal stress and a consequent basal cortisol ≥ 938 nmol/L, consisted of 
the most severely ill patients of a septic shock cohort.9 Similarly, our patients with highest 
basal cortisol levels were more often hospitalized in the ICU, had higher PSI scores and 
more comorbidities as compared to the overall cohort (see also supplemental table S2). High 
cortisol levels have been shown to be associated with worse outcome in both sepsis and 
CAP.4,7,9,21-23 Furthermore, findings of a randomized controlled study 24 and of one meta-
analysis 1 suggested that patients with most severe CAP may benefit more from 
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glucocorticoids as compared to patients with milder CAP. Therefore, our data underline the 
finding that cortisol levels can serve as a surrogate marker for severity of illness.  
Recent studies have contradicted the long-standing beliefs that in critical illness, ACTH 
levels were high in order to maintain a high cortisol production rate 6. It has been shown that 
in these patients, ACTH levels are low, probably due to negative feedback by high cortisol 
levels, and that the cortisol response to ACTH correlates positively with cortisol production 
rate, i.e. a lower rise in cosyntropin testing corresponds to a lower cortisol production rate 
and vice versa. Furthermore, critically ill patients seem to have a slower cortisol plasma 
clearance. Therefore, a possible explanation for our findings showing no predictive value of 
the cosyntropin test is that a low response to cosyntropin testing mirrors a reduced cortisol 
production and suppressed cortisol breakdown but may still result in sufficient cortisol 
availability 6.  
Recently, relatively low cortisol levels in critically ill patients, basal or after cosyntropin 
testing, have been termed sick euadrenal state 25, similarly to the frequently observed 
euthyroid sick syndrome of the thyroid 26. The euthyroid sick syndrome represents 
pathophysiological adaptations of thyroid function in severe illnes rather than a situation 
requiring thyroid substitution. The constellation of relatively low cortisol levels or a blunted 
cortisol response to cosyntropin testing in critically ill patients might rather represent 
pathophysiological adaptations of the HPA-axis than a state in need of glucocorticoid 
replacement 6,20,25.  
Our data showing no predictive value of cosyntropin testing for glucocorticoid 
responsiveness in patients with CAP underline these findings and suggest that the beneficial 
effect of glucocorticoids in CAP is rather due to the immunomodulatory effects of 
glucocorticoids than due to an effect on a presumed critical illness-related corticosteroid 
insufficiency (CIRCI). 
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Our study has the following limitations. 
First, we included hospitalized patients with CAP of any severity. This led to relatively small 
subgroups of patients with severe CAP. Therefore, the amount of critically ill patients who 
potentially fulfilled the concept of CIRCI was small as compared to other studies which were 
conducted in the ICU setting 27,28.  
Second, as a secondary subgroup analysis, even though it was preplanned, our data may be 
underpowered, and multiple testing in several subgroups may have increased the risk for 
false-positive results. 
Third, the study sites used different cortisol assays, but the study sites reported a very good 
correlation coefficient (see also Table 2). Fourth, we performed the cosyntropin test with a 
low dose of 1 µg cosyntropin, which is not the standard test and is debated controversially. 
We therefore cannot draw conclusions about a possible predictive value of the 250 µg test in 
CAP. However, recent data have shown a good correlation of the 1 µg and the 250 µg 
cosyntropin test.29,30 For the diagnosis of secondary adrenal insufficiency, i.e. due to 
inadequate ACTH secretion of the pituitary, there is even evidence that the low-dose 
cosyntropin test is more sensitive than the 250 µg cosyntropin test.29,31 In critically ill 
patients, a few but small studies have compared the low-dose cosyntropin test to the 250 µg 
cosyntropin test.30,32,33 Even though these data have shown a good correlation between the 
two methods, the low-dose cosyntropin test is so far not recommended to diagnose 
CIRCI.8,29  
 
CONCLUSION 
Neither baseline nor stimulated cortisol after low-dose cosyntropin testing at a dose of 1 µg 
predicted glucocorticoid responsiveness in mild to moderate CAP. A treatment decision for 
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or against adjunct glucocorticoids in CAP should not be made depending on cortisol values 
or cosyntropin testing results.  
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Table 1. Baseline characteristics.  
Characteristic Prednisone 
group, n=326 
Placebo group, 
n=309 
Age, mean (SD), y 73 (61-83) 72 (59-82) 
Male Gender, No. (%) 201 (62) 195 (63) 
Clinical characteristics   
Temperature, mean (SD), °C 37.5 (37.0-38.2) 37.6 (36.9-38.3) 
Systolic blood pressure, mean (SD), mmHg 124 (110-140) 125 (111-140) 
Heart rate, mean (SD), bpm 84 (74-96) 83 (71-95) 
Respiratory Rate, mean (SD), bpm 20 (18-24) 20 (18-24) 
SaO2, mean (SD), % 94 (92-96) 95 (92-96) 
Baseline data measured with oxygen administration, 
No. (%) 
159 (49) 160 (52) 
Multiple infiltrates, No. (%) 56 (17) 72 (23) 
Pleural effusion, No. (%) 36 (11) 34 (11) 
PSI class I-IIIa, No. (%) 158 (48) 166 (54) 
PSI class IV-Va, No. (%) 168 (52) 143 (46) 
Initial ICU stay 8 (2.5) 14 4.5) 
- With mechanical ventilation 3 (0.9) 8 (2.6) 
- With non-invasive ventilation 5 (1.5) 7 (2.3) 
Comorbidities   
Diabetes mellitus, No. (%) 58 (18) 62 (20) 
Chronic obstructive pulmonary disease, No. (%) 66 (20) 48 (16) 
Heart failure, No. (%) 63 (19) 48 (16) 
Cerebrovascular disease, No. (%) 34 (10) 24 (8) 
Renal insufficiency, No. (%) 102 (31) 104 (34) 
Neoplasia, No. (%) 21 (6) 19 (6) 
Laboratory values   
C-reactive protein, mean (SD), mg/L 162 (84-251) 170 (74-254) 
Procalcitonin, mean (SD), ng/mL 0.45 (0.17-2.29) 0.57 (0.18-3.05) 
Leukocytes, mean (SD), x109/L 12.1 (8.8-15.5) 11.8 (8.7-15.6) 
Adrenal function   
Baseline cortisol, mean (SD), nmol/L 573 (402-741) 563 (389-751) 
Stimulated cortisol, mean (SD), nmol/L 877 (715-1038) 849 (707-1065) 
Δcortisol, mean (SD), nmol/L 295 (188-401) 290 (301-397) 
 
aThe Pneumonia Severity Index (PSI) s a clinical prediction rule to calculate the probability of 
morbidity and mortality among patients with CAP. PSI risk class I: age 50 or less and no risk 
factors, II: < 70, III: 71-90, IV: 91-130; V: > 130 points. 
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Table 2. Cortisol assay according to study center. 
 
Study center Assay Time range 
Basel/Delémont Immulitea until May 31, 2012b 
Basel/Delémont Elecsys/Cobasc Since November 31, 2014b 
Aarau Immulitea entire study time 
Liestal/Bruderholz Beckman-Coulterd until January 16, 2012e 
Liestal/Bruderholz Elecsys/Cobasc Since January 17, 2012e 
Solothurn Beckman-Coulterd Entire study time 
Bern Elecsys/Cobasc Entire study time 
 
a IMMULITE 2000; Siemens Medical Solution Diagnostics, Los Angeles, USA. Intra-assay 
coefficient of variation (CV): 5.2-7.4%. Inter-assay CV: 6.8-9.4%. 
b in direct assay comparison at the University Hospital Basel, Switzerland with 44 patient 
samples, the correlation coefficient between assays was found to be very good (r = 0.974).  
c Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim. Intra-assay 
coefficient of variation (CV): 1.0-1.7%. Inter-assay CV: 1.4-2.8% 
d Beckman Coulter, Inc., 250 S. Kraemer Blvd., Brea, CA 92821 U.S.A. Intra-assay 
coefficient of variation (CV): 4.4-6.7%. Inter-assay CV: 6.4-7.9%. 
ein direct assay comparison at the University Hospital Liestal/Bruderholz with 33 patient 
samples, the correlation coefficient between assays was found to be very good (r=0.9920). 
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FIGURE LEGENDS 
 
Figure 1. CONSORT Study flow chart. 
 
Figure 2a. Results for the primary endpoint. 
† Cox proportional hazards model including an interaction term of the respective subgroup 
variable with treatment group. HR > 1 indicates a shorter time to clinical stability. 
CIRCI1 : baseline cortisol <275.9 nmol/L or Δcortisol < 250 nmol/L 
High risk constellation: baseline cortisol ≥ 938 nmol/L and Δcortisol < 250 nmol/L 
Modified high risk constellation: cortisol level > 571 nmol/L (median cortisol of the studied 
cohort) and Δcortisol < 250 nmol/L)  
Abbreviations: HR, hazard ratio; CI, confidence interval 
 
Figure 2b. Results for length of hospital stay. 
† Cox proportional hazards model including an interaction term of the respective subgroup 
variable with treatment group. 
CIRCI1 : baseline cortisol <275.9 or Δcortisol < 250 nmol/L 
High risk constellation: baseline cortisol ≥ 938 nmol/L and Δcortisol < 250 nmol/L 
Modified high risk constellation: cortisol level > median of 571 nmol/L and Δcortisol < 250 
nmol/L) 
Abbreviations: HR, hazard ratio; CI, confidence interval 
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Figure 2c. Results for 30-day mortality. 
† Cox proportional hazards model including an interaction term of the respective subgroup 
variable with treatment group. 
CIRCI1 : baseline cortisol <275.9 or Δcortisol < 250 nmol/L 
High risk constellation: baseline cortisol ≥ 938 nmol/L and Δcortisol < 250 nmol/L 
Modified high risk constellation: cortisol level > median of 571 nmol/L and Δcortisol < 250 
nmol/L) 
Abbreviations: HR, hazard ratio; CI, confidence interval 
 
Figure 2d. Results for CAP complications. 
CAP complications consisted of: recurrence of pneumonia, rehospitalization, ARDS, 
empyema, nosocomial infections, delirium. 
† Cox proportional hazards model including an interaction term of the respective subgroup 
variable with treatment group. 
CIRCI1 : baseline cortisol <275.9 or Δcortisol < 250 nmol/L 
High risk constellation: baseline cortisol ≥ 938 nmol/L and Δcortisol < 250 nmol/L 
Modified high risk constellation: cortisol level > median of 571 nmol/L and Δcortisol < 250 
nmol/L) 
Abbreviations: HR, hazard ratio; CI, confidence interval, CAP, community-acquired 
pneumonia  
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